These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 18333863)

  • 1. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc: in vitro assessment of drug-drug interaction potential.
    Hyland R; Dickins M; Collins C; Jones H; Jones B
    Br J Clin Pharmacol; 2008 Oct; 66(4):498-507. PubMed ID: 18647303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
    Kaeser B; Zandt H; Bour F; Zwanziger E; Schmitt C; Zhang X
    Antimicrob Agents Chemother; 2009 Feb; 53(2):609-14. PubMed ID: 19015329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):47-53. PubMed ID: 18333865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
    Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
    Abel S; van der Ryst E; Rosario MC; Ridgway CE; Medhurst CG; Taylor-Worth RJ; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):5-18. PubMed ID: 18333861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
    Buss N; Snell P; Bock J; Hsu A; Jorga K
    Br J Clin Pharmacol; 2001 Sep; 52(3):255-64. PubMed ID: 11560557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):19-26. PubMed ID: 18333862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
    Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
    King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
    J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
    MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
    HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
    Kasserra C; Sansone-Parsons A; Keung A; Tetteh E; Assaf M; O'Mara E; Marbury T
    Clin Pharmacokinet; 2010 Jun; 49(6):397-406. PubMed ID: 20481650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.